Actavis agrees to buy Botox-maker Allergan for $66bn
Under the deal, Allergan investors would receive $129.22 in cash and 0.3683 Actavis shares for each share of the Botox-maker’s common stock. The combination will create one of
GSK has entered an exclusive strategic partnership with SBP Group, via its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), to expedite the launch of bepirovirsen for chronic hepatitis B (CHB) patients in mainland China.
The project will focus on non-valvular atrial fibrillation (NVAF) and will examine disease prevalence, treatment complications, such as hospital readmissions, as well as the use of evidence-based guidelines.
Initial results are being presented this weekend to clinicians convening during the American Heart Association meeting held in Chicago, including a meeting of the Association of Black Cardiologists.